BioSpace News Archive

The Pontifax Group pursuant to which the Company raised gross proceeds of $9.5 million through the sale of approximately 8,370 shares of series A convertible preferred stock (Series A Preferred) and warrants covering 2,260 shares of Series A Preferred (Warrants).

As of September 30, 2017, the Company had $180.2 million in cash and cash equivalents.

The session, titled “Aging and Longevity,” and moderated by David Crow, Senior Business Correspondent at the Financial Times, is on Friday, November 10th at 12:10pm GMT.

Dermira to transition development and commercialization responsibility for CIMZIA (certolizumab pegol) in psoriasis back to UCB.

The Leukotide project is intended to deliver a new drug for the treatment of AML and other hematological malignancies, and is based on the company’s expertise in nucleoside and nucleotide science.

Stephens & Associates announces the appointment of Mark V. Dahl, MD, and Lawrence A. Rheins, PhD, to lead its newly-opened Phoenix research facility.

Lexicon Pharma today reported financial results for the three months ended September 30, 2017 and provided an overview of key milestones for the company’s commercial product, XERMELO, and its pipeline drug candidates.

Labcyte and the Institute for Molecular Medicine Finland announced they are extending their personalized medicine collaboration to include multiple new applications that leverage the unique capabilities of Labcyte’s Echo liquid handler and Access™ automation platform.

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

Insulet has priced a private placement of $350 million principal amount of convertible senior notes due 2024 (the Notes).